Icatibant, a selective bradykinin B2 receptor antagonist, effective and safe in treating the symptoms of hereditary angioedema (HAE) attacks

被引：4
|
作者：
Riedl, M. [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2008年 / 121卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2007.12.411
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
398
引用
收藏
页码：S103 / S103
页数：1
相关论文
共 50 条
  • [21] Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant
    Krause, Karoline
    Metz, Martin
    Zuberbier, Torsten
    Maurer, Marcus
    Magerl, Markus
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2010, 8 (04): : 272 - 274
  • [22] Self-administration of a novel subcutaneous bradykinin b2 receptor antagonist, icatibant, as an effective treatment option in patients with hereditary angioedema
    Santucci S.
    Pham H.
    Harrison R.
    Yang W.
    Allergy, Asthma & Clinical Immunology, 10 (Suppl 2)
  • [23] Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema
    Cicardi, M.
    Banerji, A.
    Bracho, F.
    Malbran, A.
    Rosenkranz, B.
    Riedl, M.
    Bork, K.
    Lumry, W.
    Aberer, W.
    Bier, H.
    Bas, M.
    Greve, J.
    Hoffmann, T. K.
    Farkas, H.
    Reshef, A.
    Ritchie, B.
    Yang, W.
    Grabbe, J.
    Kivity, S.
    Kreuz, W.
    Levy, R. J.
    Luger, T.
    Obtulowicz, K.
    Schmid-Grendelmeier, P.
    Bull, C.
    Sitkauskiene, B.
    Smith, W. B.
    Toubi, E.
    Werner, S.
    Anne, S.
    Bjorkander, J.
    Bouillet, L.
    Cillari, E.
    Hurewitz, D.
    Jacobson, K. W.
    Katelaris, C. H.
    Maurer, M.
    Merk, H.
    Bernstein, J. A.
    Feighery, C.
    Floccard, B.
    Gleich, G.
    Hebert, J.
    Kaatz, M.
    Keith, P.
    Kirkpatrick, C. H.
    Langton, D.
    Martin, L.
    Pichler, C.
    Resnick, D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (06): : 532 - 541
  • [24] First use of icatibant (selective bradykinin receptor antagonist) in hereditary angioedema patients in the UK
    Karanam, S.
    Demptser, J.
    Longhurst, H.
    Gompels, M.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2009, 39 (12): : 1943 - 1943
  • [25] Novel pharmacotherapy of acute hereditary angioedema with bradykinin B2-receptor antagonist icatibant
    Bas, M.
    Bier, H.
    Greve, J.
    Kojda, G.
    Hoffmann, T. K.
    ALLERGY, 2006, 61 (12) : 1490 - 1492
  • [26] Safety Evaluation of Icatibant, a Selective Bradykinin B2 Receptor Antagonist Used in Hereditary Angioedema Due to C1 Inhibitor Deficiency
    Staubach, P.
    Bork, K.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S100 - S100
  • [27] Treatment of laryngopharyngeal and lingual hereditary angioedema with bradykinin-B2-receptor-antagonist icatibant
    Bas, M.
    Greve, J.
    Kojda, G.
    Bier, H.
    Hoffmann, K.
    ALLERGY, 2007, 62 : 95 - 95
  • [28] Treatment of hereditary angioedema due to C1 inhibitor deficiency with Icatibant, a selective bradykinin B2 receptor antagonist: a safety perspective
    Bork, K.
    ALLERGY, 2008, 63 : 47 - 47
  • [29] Treatment of patients with acute attacks of hereditary angioedema due to C1-INH deficiency with the bradykinin B2 receptor-antagonist Icatibant
    Farkas, H.
    Varga, L.
    Szeplaki, G.
    Temesszentandrasi, G.
    Jakab, L.
    Fekete, B.
    Fust, G.
    Karadi, L.
    ALLERGY, 2008, 63 : 474 - 475
  • [30] Proof-of-concept study of icatibant (JE 049), a bradykinin B2 receptor antagonist in treatment of hereditary angioedema.
    Rosenkranz, B
    Bork, K
    Frank, J
    Kreuz, W
    Dong, L
    Knolle, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P14 - P14
12345